Guardant Health Market Research Report

Company Overview

• Name: Guardant Health

• Mission of the Company: To conquer cancer with data by transforming cancer care through blood-based testing, which provides the critical insights needed at all stages of cancer for patients and healthcare providers.

• Founding Information: No information is available.

• Key People: Helmy Eltoukhy, co-Chief Executive Officer (co-CEO)

• Headquarters: 3100 Hanover Street, Palo Alto, CA 94304

• Number of Employees: No information is available.

• Revenue: No information is available.

• Company Recognition: Guardant Health is recognized for advancing blood-based cancer screenings and precision oncology through their proprietary technology, focusing prominently on molecular diagnostics.

Products

1. Shield™ Blood Test

• Description: The first FDA-approved blood test for colon cancer screening, covered by Medicare. Shield is designed to improve screening accessibility and accuracy by detecting very early signs of colorectal cancer through genomic, methylation, and fragmentomic analyses from a simple blood draw.

• Key Features:

• High sensitivity and specificity for early cancer detection.

• Overcomes barriers associated with traditional screening methods like colonoscopy.

2. Guardant360® Portfolio

• Guardant360 CDx:

• Description: FDA-approved liquid biopsy enabling guideline-recommended complete genomic testing for advanced solid tumors.

• Key Features: Fast results in less than 7 days; broad commercial and Medicare coverage.

• Guardant360 TissueNext:

• Description: Tissue biopsy test utilizing AI for PD-L1 detection in non-small cell lung cancer (NSCLC).

• Key Features: Enhances PD-L1 detection accuracy by >20%; suitable for advanced solid tumors.

• Guardant Reveal®:

• Description: Tissue-free test for detecting minimal residual disease (MRD) via ctDNA in early-stage cancers like colorectal, breast, and lung.

• Key Features: Assesses MRD and monitors recurrence.

• Guardant360 Response:

• Description: The first tissue-free biopsy for measuring treatment response.

• Key Features: Provides early indications of patient responses to therapies, predicting treatment outcomes earlier than conventional methods.

3. Biopharma Solutions

• Description: Designed to accelerate precision oncology in drug development by offering comprehensive genomic and epigenomic profiling solutions.

• Key Features: Provides translational research support, accelerates clinical development, and improves real-world evidence generation.

Recent Developments

• Recent Developments:

• FDA Approval: Shield™ Blood Test has been approved by the FDA as a primary colorectal cancer screening option, making it eligible for Medicare reimbursement.

• Product Upgrade: Guardant Health has introduced a significant upgrade to the Guardant360® Test, enhancing its performance as a leading liquid biopsy tool.

• New Products Launched:

• No new products beyond enhancements to existing tests are noted.

• New Features Added to Existing Products:

• AI enhancement for PD-L1 detection in the Guardant360 TissueNext test.

• Partnerships and Collaborations:

• No explicit new partnerships are mentioned.

This report encapsulates the vital aspects of Guardant Health’s operations, highlighting its significant innovations and progress in cancer care through cutting-edge blood-based diagnostics. The company's ongoing contributions to precision oncology and comprehensive solutions are reflective of their mission to make a transformative impact in cancer care.